Search results for "GLP-1RA"

showing 6 items of 6 documents

The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism

2021

ABSTRACT Introduction A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for man…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)coronavirusSARS-COV-2PharmacologyIncretinsGlucagonGlucagon-Like Peptide-1 ReceptorAnimalsHumansHypoglycemic AgentsMedicinePharmacology (medical)ReceptorSpecial ReportGlucagon-like peptide 1 receptortherapyPandemicdiabetesSARS-CoV-2business.industrypandemicDiabetesCOVID-19General MedicineGLP-1RAcoronavirus diabetes GLP-1RA pandemic SARS-COV-2 therapy Animals COVID-19Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Signal Transduction Treatment OutcomeCOVID-19 Drug TreatmentCoronavirusTreatment OutcomeDiabetes Mellitus Type 2Molecular mechanismbusinessResearch ArticleSignal Transduction
researchProduct

Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from a…

2021

Aims: Evidence from cardiovascular outcomes trials (CVOTs) of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors was reflected in the most recent guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The aim of the present study was to assess the adoption of the ADA/EASD guidelines in a convenience sample of physicians from Eastern and Southern Europe, the barriers to the implementation of these guidelines and the measures needed to facilitate their implementation. Methods: Attendees at two international diabetes conferences could volunteer to respond to a fully anonymous survey. Responses …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismConvenience sampleSurvey resultGuidelines as Topic03 medical and health sciences0302 clinical medicineEndocrinologyPhysiciansSurveys and QuestionnairesInternal MedicineMedicineHumansAdherence Clinical guidelines GLP-1RAs SGLT2is Type 2 diabetes Europe Europe Eastern Female Guidelines as Topic Humans Male Physicians Surveys and Questionnaires030212 general & internal medicineEurope EasternReimbursementAmerican diabetes associationbusiness.industryGeneral Medicine3. Good healthEuropePublishingFamily medicinePhysician surveyGood clinical practiceFemalebusinessCardiovascular outcomesDiabetes research and clinical practice
researchProduct

Insulin withdrawal in diabetic kidney disease : What are we waiting for?

2021

The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease (CKD), and these patients often present high morbidity and mortality rates, particularly in those patients with poorly controlled risk factors. Furthermore, many are overweight or obese, due primarily to insulin compensation resulting from insulin resistance. In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular targets; however…

Opinionmedicine.medical_specialtyinsulinHealth Toxicology and Mutagenesismedicine.medical_treatmentRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologyOverweight03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseInternal medicinemedicineHumansHypoglycemic AgentsInsulinDiabetic NephropathiesSGLT2iDiabetic kidney diseaseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetisbusiness.industryInsulinMortality ratePublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseRepaglinideCardiovascular diseaseGLP-1RAdiabetic kidney diseaseCor MalaltiesDiabetes Mellitus Type 2Medicinemedicine.symptombusinessKidney diseasemedicine.drug
researchProduct

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

2021

Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in p…

SenescenceEndocrinology Diabetes and MetabolismAdipose tissueInflammationGlycemic ControlReview ArticleDiseaseBioinformaticsDiseases of the endocrine glands. Clinical endocrinologyGlucagon-Like Peptide-1 ReceptorProinflammatory cytokineEndocrinologySodium-glucose cotransporter 2 inhibitors (SGLT2i)Weight lossDiabetes mellitusmedicineHumansSodium-Glucose Transporter 2 InhibitorsCellular SenescenceGlycemicInflammationMetabolic SyndromeManagement of diabetesRonyonsDiabetisbusiness.industryRC648-665medicine.diseaseCor MalaltiesAdipose TissueantihyperglycemicPatients obesity and cardiorenal compromiseglycemic controlmedicine.symptombusinessGlucagon-like peptide 1 receptor agonists (GLP-1RA)
researchProduct

COVID-19 and diabetes management: What should be considered?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Clinical effectivenessbusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular disease COVID-19 Diabetes DPP4 GLP-1RA Hydroxychloroquine Pioglitazone SGLT-2General Medicinemedicine.diseaseEndocrinologyDiabetes managementDiabetes mellitusInternal MedicinemedicineSodium-Glucose Cotransporter 2 InhibitorIntensive care medicinebusinessPioglitazonemedicine.drugDiabetes research and clinical practice
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct